Clinical trials: Acute Cardiac Syndrome
Acute Coronary Artery Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT02347098)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 4 sites in United States
- Volunteers
- 270 people
- Sponsor
- VA Office of Research and Development
Acute Coronary Syndrome
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
- Trial name
- NCT00830960
- Testing
- Prasugrel, Clopidogrel
- Where
- 19 sites in China, South Korea and 2 more
- Volunteers
- 720 people
- Sponsor
- Eli Lilly and Company
Hypertension, HIV
Community Health Worker Optimization of Antihypertensive Care in HIV
To adapt and assess the implementation and preliminary effectiveness of an integrated COBRA and CHAMP multi-component community health worker-delivered hypertension intervention in improving blood pressure control among PLWH in…
- Trial name
- COACH (NCT06503991)
- Testing
- Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP), Control of Blood Pressure and Risk Attenuation (COBRA)
- Where
- Tanzania
- Volunteers
- 100 people
- Sponsor
- Duke University
Acute Coronary Syndrome
Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome
In this proof-of-concept study, the investigators will assess the ease and usefulness of a positive psychology program in patients with acute coronary syndrome and less-than-optimal adherence to health behaviors.
- Trial name
- PEACE II (NCT02004158)
- Testing
- Positive psychology intervention
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.
- Trial name
- NCT00552188
- Testing
- VIA-2291
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Acute Coronary Syndrome
Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
This purpose of this study is to measure platelet response to ticagrelor and eptifibatide bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion administrated after cardiac catheterization in patients…
- Trial name
- NCT01919723
- Testing
- Ticagrelor, Eptifibatide
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of Alabama at Birmingham
Acute Coronary Syndrome
Evolocumab in Acute Coronary Syndrome
Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient…
- Trial name
- EVACS (NCT03515304)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Acute Coronary Syndrome, Cardiovascular Diseases
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention
This is a randomized, prospective, open label study to determine the cost-effectiveness of genotype-guided antiplatelet therapy.
- Trial name
- ADAPT (NCT02508116)
- Testing
- CYP2C19 genotyping
- Where
- 2 sites in United States
- Volunteers
- 509 people
- Sponsor
- University of Pennsylvania
Heart Disease, Coronary, Chest Pain
The Computed Tomography-derived Fractional Flow Reserve STAT Trial
This study is designed to directly compare Standard Care and CT fractional flow reserve (CTFFR) for diagnosis of chest pain patients with definite coronary artery disease (CAD) on heart computed tomography (CT) scans.
- Conditions
- Heart Disease, Coronary, Chest Pain, Acute Coronary Syndrome
- Trial name
- CTFFR-STAT (NCT03263806)
- Testing
- CTFFR-Guided Group Management, SOC Group Management
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Corewell Health East
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome, Lipid Disorder
Polypill in Acute Coronary Syndrome
Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low.
- Conditions
- Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
- Trial name
- POLY-ACS (NCT05514938)
- Testing
- Polypill, Usual Care (individual medications prescribed by primary cardiologist)
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Coronary Syndrome
Early Risk Stratification in ED Chest Pain Patients
In the management of adult chest pain patients presenting to an Emergency Department (ED) with suspected acute coronary syndrome (ACS), we aimed to evaluate the diagnostic accuracy of the combined use of a modified Thrombolysis…
- Trial name
- NCT02364271
- Testing
- Thrombolysis in myocardial infarction score, routine blood test for hs-cTnT, HEART score
- Where
- China
- Volunteers
- 602 people
- Sponsor
- Chinese University of Hong Kong
Sleep Apnea
Mapping for Acute Transvenous Phrenic Nerve Stimulation Study
The Mapping for Transvenous Phrenic Nerve Stimulation Study (MAPS) is being conducted to evaluate the feasibility of transvascular stimulation of phrenic nerves via an electrophysiology (EP) catheter advanced into the great veins.
- Trial name
- MAPs (NCT01981590)
- Testing
- Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 15 people
- Sponsor
- Medtronic BRC
Acute Coronary Syndrome, Sleep Disorder
Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome
The purpose of the study is to examine the effects of Eszopiclone, a sleep aid, on inflammatory mediators and coagulability in patients with a recent myocardial infarction.
- Trial name
- NCT00822679
- Testing
- Eszopiclone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Arizona
Acute Coronary Syndrome, Fear Anxiety
The Reducing Exercise Sensitivity With Exposure Training (RESET) Study
This study investigates the feasibility of conducting a home-based reducing exercise sensitivity with exposure training (RESET) intervention among acute coronary syndrome (ACS) survivors.
- Conditions
- Acute Coronary Syndrome, Fear Anxiety, Physical Inactivity
- Trial name
- RESET (NCT05099926)
- Testing
- Reducing Exercise Sensitivity with Exposure Training
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Heart Failure, Acute Heart Failure
PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure
This study evaluates whether tailored, peripheral ultrafiltration complementary to low-dose diuretics is associated with a reduction in cardiovascular mortality in 90 days after randomization and heart failure events in 90 days…
- Trial name
- NCT03161158
- Testing
- CHIARA-System, Usual care IV diuretics
- Where
- 11 sites in Germany, Sweden
- Volunteers
- 62 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects.
- Trial name
- HARMONEE (NCT02073565)
- Testing
- OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
- Where
- 50 sites in United States, Japan
- Volunteers
- 572 people
- Sponsor
- OrbusNeich
Depression
Treatment of Depression in Acute Coronary Syndrome (ACS) Patients
Emotional states of depression in association with ischemic heart diseases, such as myocardial infarction or unstable angina, are risk factors for subsequent cardiac events and mortality.
- Trial name
- TREATED-ACS (NCT00998400)
- Testing
- CBT in combination with WBT and life style modification
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna